Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Latest Information Update: 14 Jan 2025
At a glance
- Drugs Adavosertib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
Most Recent Events
- 09 Jan 2025 Status changed from active, no longer recruiting to completed.
- 11 Feb 2021 Planned primary completion date changed from 29 Jan 2021 to 30 Jun 2021.
- 11 Jun 2020 Status changed from recruiting to active, no longer recruiting.